Business Daily Folgen

As the Taliban takes control of Afghanistan this week, we ask what the future holds for the country. The central bank governor, Ajmal Ahmady, who fled earlier this week, tells us about the days and weeks leading up to the takeover. Dr Weeda Mehran from the University of Exeter outlines how the country arrived at this point, and what the future could hold. She argues that unless the Taliban gains legitimacy internationally it will struggle to govern effectively or grow the economy. Plus, a new Alzheimer's drug has been approved by the FDA in the US, but lawmakers are looking at how and why it was approved so quickly. Apple’s decision to scan users’ phones for images of child abuse has privacy campaigners worried - and we’ll hear from the businesses busy preparing for Christmas 2021. Business Weekly is produced by Clare Williamson and presented by Lucy Burton. (Image: Afghans gather outside the Hamid Karzai International Airport in Kabul to flee the country, Image credit: European Pressphoto Agency)

All our lives are ruled by time and it's a fundamental part of our daily routines but what if we could make time go more slowly - or quickly? Adrian Bejan, a professor in thermodynamics at Duke University says that this is possible if we just open our minds to how we perceive change. And if we could make time last longer, what would be the most efficient way of using it? We get some tips from Laura Vanderkam a writer and speaker on time management. Plus, research scientist Christian Clot tells us about an experiment where all markers of time were taken away, including clocks, watches and sunlight - and what that could mean for how we live in the future. And casino designer and consultant, Bill Friedman explains how the idea of timelessness is put to practical use in casinos where professional gamblers want to feel that they're always in the moment. Picture: antique clocks, Picture credit: Getty ImagesPresenter: Elizabeth Hotson Producer: Sarah Treanor

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harvard Medical School professor, served on the FDA’s advisory committee that considered Aduhelm and voted against its approval. He explains why he decided to resign from his post and what consequences there could be for future research and also for Medicare and Medicaid for covering such an expensive drug.Geri Taylor has participated in the Aduhelm trial since 2015 and both her and her husband Jim believe that the drug has slowed her decline.Jason Karlawish - a practising physician, co-director of the Penn Memory Centre and the author of The Problem of Alzheimer’s book - says that more money should be spent on providing carers for the vast majority of Alzheimer's patients and that people should not be forced to choose between cure and care. PHOTO: 3d illustration of the human brain with Alzheimer’s disease/Getty Images